Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J. Palomino is active.

Publication


Featured researches published by J. Palomino.


Clinical Infectious Diseases | 2013

A Large Multicenter Study of Methicillin–Susceptible and Methicillin–Resistant Staphylococcus aureus Prosthetic Joint Infections Managed With Implant Retention

Jaime Lora-Tamayo; Oscar Murillo; José Antonio Iribarren; Alex Soriano; Mar Sánchez-Somolinos; Josu Miren Baraia-Etxaburu; Alicia Rico; J. Palomino; Dolors Rodríguez-Pardo; Juan Pablo Horcajada; Natividad Benito; Alberto Bahamonde; Ana Granados; María Dolores del Toro; Javier Cobo; Melchor Riera; Antonio Ramos; Alfredo Jover-Sáenz; Javier Ariza

BACKGROUND Several series predicting the prognosis of staphylococcal prosthetic joint infection (PJI) managed with debridement, antibiotics, and implant retention (DAIR) have been published, but some of their conclusions are controversial. At present, little is known regarding the efficacy of the different antibiotics that are used or their ability to eliminate methicillin-resistant S. aureus (MRSA) infection. METHODS This was a retrospective, multicenter, observational study of cases of PJI by S. aureus that were managed with DAIR (2003-2010). Cases were classified as failures when infection persistence/relapse, death, need for salvage therapy, or prosthesis removal occurred. The parameters that predicted failure were analyzed with logistic and Cox regression. RESULTS Out of 345 episodes (41% men, 73 years), 81 episodes were caused by MRSA. Fifty-two were hematogenous, with poorer prognoses, and 88% were caused by methicillin-susceptible S. aureus (MSSA). Antibiotics were used for a median of 93 days, with similar use of rifampin-based combinations in MSSA- and MRSA-PJI. Failure occurred in 45% of episodes, often early after debridement. The median survival time was 1257 days. There were no overall prognostic differences between MSSA- and MRSA-PJI, but there was a higher incidence of MRSA-PJI treatment failure during the period of treatment (HR 2.34), while there was a higher incidence of MSSA-PJI treatment failure after therapy. Rifampin-based combinations exhibited an independent protective effect. Other independent predictors of outcome were polymicrobial, inflammatory, and bacteremic infections requiring more than 1 debridement, immunosuppressive therapy, and the exchange of removable components of the prosthesis. CONCLUSIONS This is the largest series of PJI by S. aureus managed with DAIR reported to date. The success rate was 55%. The use of rifampin may have contributed to homogenizing MSSA and MRSA prognoses, although the specific rifampin combinations may have had different efficacies.


Clinical Microbiology and Infection | 2011

Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy

J. Cobo; L. García San Miguel; Gorane Euba; Dolors Rodríguez; J. García-Lechuz; Melchor Riera; L. Falgueras; J. Palomino; Natividad Benito; M.D. del Toro; Carlos Pigrau; Javier Ariza

Recent expert reviews recommend a conservative surgical strategy - debridement and irrigation, antibiotics and implant retention (DAIR) - for most early post-surgical prosthetic joint infections (PJI). However, differences exist in published series regarding success rates with DAIR, and the size of most series is small. In this prospective multicenter cohort study of early PJI managed by DAIR, factors associated with failure of the DAIR were analyzed. Out of 139 early PJI, 117 cases managed with DAIR were studied For 67 patients (57.3%), infection was cured and the implant was salvaged with definite antimicrobial therapy. In 35 (29.9%) DAIR failed and removal of the prosthesis was necessary during follow-up. Finally, 15 patients (12.8%) needed chronic suppressive antimicrobial therapy due to suspected or confirmed persistent infection. Infections due to methicillin-resistant S. aureus (72.7% failed; p 0.05) and those treated at one of the hospitals (80.0% failed; p <0.05) had worse outcomes, but only this last variable was associated with treatment failure following multivariate analysis. Seventy-four per cent of patients who were successfully treated by DAIR and only 32.7% of the failures were able to walk without help or with one stick at the last follow-up visit (p <0.05). In conclusion, a substantial proportion of patients with an early PJI may be successfully treated with DAIR and definite antimicrobial therapy. In more than half of these, the infection can be cured. Since identification of factors associated with failure of DAIR is not simple, we recommend offering DAIR to most patients with early PJI.


Clinical Microbiology and Infection | 2010

Acute haematogenous prosthetic joint infection: prospective evaluation of medical and surgical management

Dolors Rodríguez; Carlos Pigrau; Gorane Euba; J. Cobo; J. García-Lechuz; J. Palomino; Melchor Riera; M.D. del Toro; Ana Granados; X. Ariza

The optimum treatment for prosthetic joint infections has not been clearly defined. We report our experience of the management of acute haematogenous prosthetic joint infection (AHPJI) in patients during a 3-year prospective study in nine Spanish hospitals. Fifty patients, of whom 30 (60%) were female, with a median age of 76 years, were diagnosed with AHPJI. The median infection-free period following joint replacement was 4.9 years. Symptoms were acute in all cases. A distant previous infection and/or bacteraemia were identified in 48%. The aetiology was as follows: Staphylococcus aureus, 19; Streptococcus spp., 14; Gram-negative bacilli, 12; anaerobes, two; and mixed infections, three. Thirty-four (68%) patients were treated with a conservative surgical approach (CSA) with implant retention, and 16 had prosthesis removal. At 2-year follow-up, 24 (48%) were cured, seven (14%) had relapsed, seven (14%) had died, five (10%) had persistent infection, five had re-infection, and two had an unknown evolution. Overall, the treatment failure rates were 57.8% in staphylococcal infections and 14.3% in streptococcal infections. There were no failures in patients with Gram-negative bacillary. By multivariate analysis, CSA was the only factor independently associated with treatment failure (OR 11.6; 95% CI 1.29-104.8). We were unable to identify any factors predicting treatment failure in CSA patients, although a Gram-negative bacillary aetiology was a protective factor. These data suggest that although conservative surgery was the only factor independently associated with treatment failure, it could be the first therapeutic choice for the management of Gram-negative bacillary and streptococcal AHPJI, and for some cases with acute S. aureus infections.


Clinical Infectious Diseases | 2017

The Not-So-Good Prognosis of Streptococcal Periprosthetic Joint Infection Managed by Implant Retention: The Results of a Large Multicenter Study

Jaime Lora-Tamayo; E. Senneville; Alba Ribera; Louis Bernard; Michel Dupon; Valérie Zeller; Ho Kwong Li; Cédric Arvieux; Martin Clauss; Ilker Uckay; Dace Vigante; Tristan Ferry; José Antonio Iribarren; Trisha N. Peel; Parham Sendi; Nina Gorišek Miksić; Dolors Rodríguez-Pardo; María Dolores del Toro; Marta Fernández-Sampedro; Ulrike Dapunt; Kaisa Huotari; Joshua S. Davis; J. Palomino; Daniëlle Neut; Benjamin Clark; Thomas Gottlieb; Rihard Trebše; Alex Soriano; Alberto Bahamonde; Laura Guío

Background. Streptococci are not an infrequent cause of periprosthetic joint infection (PJI). Management by debridement, antibiotics, and implant retention (DAIR) is thought to produce a good prognosis, but little is known about the real likelihood of success. Methods. A retrospective, observational, multicenter, international study was performed during 2003-2012. Eligible patients had a streptococcal PJI that was managed with DAIR. The primary endpoint was failure, defined as death related to infection, relapse/persistence of infection, or the need for salvage therapy. Results. Overall, 462 cases were included (median age 72 years, 50% men). The most frequent species was Streptococcus agalactiae (34%), and 52% of all cases were hematogenous. Antibiotic treatment was primarily using β-lactams, and 37% of patients received rifampin. Outcomes were evaluable in 444 patients: failure occurred in 187 (42.1%; 95% confidence interval, 37.5%-46.7%) after a median of 62 days from debridement; patients without failure were followed up for a median of 802 days. Independent predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infection (2.20), and bacteremia (1.69). Independent predictors of success were exchange of removable components (0.60), early use of rifampin (0.98 per day of treatment within the first 30 days), and long treatments (≥21 days) with β-lactams, either as monotherapy (0.48) or in combination with rifampin (0.34). Conclusions. This is the largest series to our knowledge of streptococcal PJI managed by DAIR, showing a worse prognosis than previously reported. The beneficial effects of exchanging the removable components and of β-lactams are confirmed and maybe also a potential benefit from adding rifampin.


Diagnostic Microbiology and Infectious Disease | 2013

Linezolid in late-chronic prosthetic joint infection caused by gram-positive bacteria

Javier Cobo; Jaime Lora-Tamayo; Gorane Euba; Alfredo Jover-Sáenz; J. Palomino; MªDolores del Toro; Dolors Rodríguez-Pardo; Melchor Riera; Javier Ariza

Linezolid may be an interesting alternative for prosthetic joint infection (PJI) due to its bioavailability and its antimicrobial spectrum. However, experience in this setting is scarce. The aim of the study was to assess linezolids clinical and microbiological efficacy, and also its tolerance. This was a prospective, multicenter, open-label, non-comparative study of 25 patients with late-chronic PJI caused by Gram-positive bacteria managed with a two-step exchange procedure plus 6 weeks of linezolid. Twenty-two (88%) patients tolerated linezolid without major adverse effects, although a global decrease in the platelet count was observed. Three patients were withdrawn because of major toxicity, which reversed after linezolid stoppage. Among patients who completed treatment, 19 (86%) demonstrated clinical and microbiological cure. Two patients presented with clinical and microbiological failure, and one showed clinical cure and microbiological failure. In conclusion, linezolid showed good results in chronic PJI managed with a two-step exchange procedure. Tolerance seems acceptable, though close surveillance is required.


Clinical Infectious Diseases | 2017

Long-Term Impact of an Educational Antimicrobial Stewardship Program on Hospital-Acquired Candidemia and Multidrug-Resistant Bloodstream Infections: A Quasi-Experimental Study of Interrupted Time-Series Analysis

José Molina; Germán Peñalva; María V. Gil-Navarro; Julia Praena; José Antonio Lepe; María Antonia Pérez-Moreno; Carmen Ferrándiz; Teresa Aldabó; Manuela Aguilar; Peter Olbrich; Manuel E. Jiménez-Mejías; María L Gascón; Rosario Amaya-Villar; Olaf Neth; María Jesús Rodríguez-Hernández; Antonio Gutiérrez-Pizarraya; José Garnacho-Montero; Cristina Montero; Josefina Cano; J. Palomino; Raquel Valencia; Rocío Álvarez; Elisa Cordero; Marta Herrero; José Miguel Cisneros; Julián Palomino; Emilio García-Cabrera; Francisco Porras; Francisco Jiménez-Parrilla; Ignacio Obando

Background The global crisis of bacterial resistance urges the scientific community to implement intervention programs in healthcare facilities to promote an appropriate use of antibiotics. However, the clinical benefits or the impact on resistance of these interventions has not been definitively proved. Methods We designed a quasi-experimental intervention study with an interrupted time-series analysis. A multidisciplinary team conducted a multifaceted educational intervention in our tertiary-care hospital over a 5-year period. The main activity of the program consisted of peer-to-peer educational interviews between counselors and prescribers from all departments to reinforce the principles of the proper use of antibiotics. We assessed antibiotic consumption, incidence density of Candida and multidrug-resistant (MDR) bacteria bloodstream infections (BSIs) and their crude death rate per 1000 occupied bed days (OBDs). Results A quick and intense reduction in antibiotic consumption occurred 6 months after the implementation of the intervention (change in level, -216.8 defined daily doses per 1000 OBDs; 95% confidence interval, -347.5 to -86.1), and was sustained during subsequent years (average reduction, -19,9%). In addition, the increasing trend observed in the preintervention period for the incidence density of candidemia and MDR BSI (+0.018 cases per 1000 OBDs per quarter; 95% confidence interval, -.003 to .039) reverted toward a decreasing trend of -0.130 per quarter (change in slope, -0.029; -.051 to -.008), and so did the mortality rate (change in slope, -0.015; -.021 to -.008). Conclusions This education-based antimicrobial stewardship program was effective in decreasing the incidence and mortality rate of hospital-acquired candidemia and MDR BSI through sustained reduction in antibiotic use.


Enfermedades Infecciosas Y Microbiologia Clinica | 2017

Consensus statementExecutive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)Resumen ejecutivo de tratamiento de las infecciones de prótesis articulares. Guia clínica práctica de la Sociedad Española de Enfermedades Infecciosas y Microbiologia Clínica

Javier Ariza; Javier Cobo; Josu Baraia-Etxaburu; Natividad Benito; Guillermo Bori; J. Cabo; Pablo S. Corona; Jaime Esteban; Juan Pablo Horcajada; Jaime Lora-Tamayo; Oscar Murillo; J. Palomino; Jorge Parra; Carlos Pigrau; José Luis del Pozo; Melchor Riera; Dolores Rodríguez; Mar Sánchez-Somolinos; Basilio de la Torre

The incidence of prosthetic joint infection (PJI) is expected to increase in the coming years. PJI has serious consequences for patients, and high costs for the health system. The complexity of these infections makes it necessary to organize the vast quantity of information published in the last several years. The indications for the choice of a given surgical strategy and the corresponding antimicrobial therapy are specifically reviewed. The authors selected clinically relevant questions and then reviewed the available literature in order to give recommendations according to a pre-determined level of scientific evidence. The more controversial aspects were debated, and the final composition was agreed at an ad hoc meeting. Before its final publication, the manuscript was made available online in order that all SEIMC members were able to read it and make comments and suggestions.


Clinical Microbiology and Infection | 2014

Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study

Dolors Rodríguez-Pardo; Carlos Pigrau; Jaime Lora-Tamayo; Alex Soriano; M.D. del Toro; J. Cobo; J. Palomino; Gorane Euba; Melchor Riera; Mar Sánchez-Somolinos; Natividad Benito; M. Fernández-Sampedro; L. Sorli; L. Guio; José Antonio Iribarren; Josu Baraia-Etxaburu; Antonio Ramos; Alberto Bahamonde; X. Flores-Sánchez; Pablo S. Corona; Javier Ariza


Clinical Microbiology and Infection | 2014

Characteristics of prosthetic joint infections due to Enterococcus sp. and predictors of failure: a multi-national study

E. Tornero; E. Senneville; Gorane Euba; S. Petersdorf; Dolors Rodríguez-Pardo; B. Lakatos; M.C. Ferrari; M. Pilares; Alberto Bahamonde; R. Trebse; Natividad Benito; L. Sorli; M.D. del Toro; Josu Baraia-Etxaburu; Antonio Ramos; Melchor Riera; Alfredo Jover-Sáenz; J. Palomino; Javier Ariza; Alex Soriano


European Journal of Clinical Microbiology & Infectious Diseases | 2014

Are hip hemiarthroplasty and total hip arthroplasty infections different entities? The importance of hip fractures

M.D. del Toro; I. Nieto; Francisco Guerrero; Juan E. Corzo; A. del Arco; J. Palomino; Enrique Nuño; J.M. Lomas; Clara Natera; J. M. Fajardo; J. Delgado; M. Torres-Tortosa; A. Romero; Patricia Martín-Rico; Miguel A. Muniain; Jesús Rodríguez-Baño

Collaboration


Dive into the J. Palomino's collaboration.

Top Co-Authors

Avatar

Melchor Riera

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar

Javier Ariza

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Gorane Euba

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Carlos Pigrau

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M.D. del Toro

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

Natividad Benito

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Alex Soriano

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Dolors Rodríguez

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge